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Abstract
Background: Non-invasive ventilation (NIV) improves survival and quality of life in amyotrophic lateral sclerosis (ALS)
patients. The timing of referral to a home ventilation service (HVS), which is in part based on respiratory function tests,
has shown room for improvement. It is currently unknown which respiratory function test predicts an appropriate
timing of the initiation of NIV.
Methods: We analysed, retrospectively, serial data of five respiratory function tests: forced vital capacity (FVC), peak
cough flow (PCF), maximum inspiratory and expiratory pressure (MIP and MEP) and sniff nasal inspiratory pressure (SNIP)
in patients with ALS. Patients who had had at least one assessment of respiratory function and one visit at the
HVS, were included. Our aim was to detect the test with the highest predictive value for the need for elective NIV
in the following 3 months. We analysed time curves, currently used cut-off values for referral, and respiratory function
test results between ‘NIV indication’ and ‘no-NIV indication’ patients.
Results: One hundred ten patients with ALS were included of whom 87 received an NIV indication; 11.5% had
one assessment before receiving an NIV indication, 88.5% had two or more assessments. The NIV indication was
based on complaints of hypoventilation and/or proven (nocturnal) hypercapnia. The five respiratory function tests
showed a descending trend during disease progression, where SNIP showed the greatest decline within the latest
3 months before NIV indication (mean = −22%). PCF at the time of referral to the HVS significantly discriminated
between the groups ‘NIV-indication’ and ‘no NIV-indication yet’ patients at the first HVS visit: 259 (±92) vs. 348
(±137) L/min, p = 0.019. PCF and SNIP showed the best predictive characteristics in terms of sensitivity.
Conclusion: SNIP showed the greatest decline prior to NIV indication and PCF significantly differentiated ‘NIV-
indication’ from ‘no NIV-indication yet’ patients with ALS. Currently used cut-off values might be adjusted and
other respiratory function tests such as SNIP and PCF may become part of routine care in patients with ALS in
order to avoid non-timely initiation of (non-invasive) ventilation.
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Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disorder, characterized by progressive muscle
weakness, including the respiratory muscles. Respiratory
muscle weakness often starts as nocturnal hypoventilation
during sleep and symptoms can be treated with non-
invasive ventilation (NIV), which improves survival and
quality of life in a selection of patients with ALS [1, 2].
The initiation of NIV is partly based on complaints of
nocturnal hypoventilation, such as morning headache,
daytime sleepiness and loss of concentration or memory.
These complaints are not specific and may even be absent,
which may lead clinicians to rely, in addition, on daytime
tests of respiratory muscle function or pulmonary func-
tion [3]. Although new methods are being investigated in
ALS (e.g. nocturnal capnography and oxymetry), this is
not current practice in most hospitals; the forced vital cap-
acity (FVC) is the most frequently used respiratory func-
tion test in patients with ALS [4, 5]. A recent study in the
Netherlands showed that 37% of the patients with ALS, at
their first visit at a home ventilation service (HVS), already
had a level of respiratory impairment that lead to an out-
right NIV indication, either elective (<3 weeks; 19%), or
even in a (sub)acute setting (in 18%) [4].
Ideally, patients with ALS should be referred to an HVS,
at least three months before receiving an NIV indication.
Then, patients, relatives and physicians can make a con-
sidered decision about all possible treatment options [6].
It is not entirely investigated which respiratory function
test enables appropriate timing of the referral and indica-
tion of NIV in ALS [7, 8]. Compared to the FVC, the sniff
nasal inspiratory pressure (SNIP) provides more accurate
prognostic information on mortality in patients with ALS,
but its value for the prediction of an NIV indication has
not been studied in a large ALS cohort [9–13]. An im-
paired cough is associated with a higher risk for deve-
loping respiratory complications. Peak cough flow (PCF)
estimates cough efficacy and airway clearance and may
help decisions regarding cough augmentation. The role of
PCF in predicting the need for NIV is not yet fully cla-
rified [14–16]. Furthermore, the maximum inspiratory
and expiratory pressures (MIP and MEP) may have a
higher sensitivity for nocturnal hypoventilation compared
to the FVC in patients with ALS [17, 18]. We hypothe-
sized that a decline in one of the respiratory function tests,
may predict an NIV indication in patients with ALS
within the following three months. Therefore, we aimed
to examine serial data of FVC, PCF, MIP, MEP and SNIP
for the prediction of the need for NIV.
Methods
Patients
This study was performed at the Radboud university
medical centre (Radboudumc) in Nijmegen and the HVS
in Utrecht (2 patients switched to another HVS as they
moved places; data of these patients were retrieved from
their HVS in Groningen and Maastricht).
Inclusion criteria were a diagnosis of definite ALS, ac-
cording to the El Escorial criteria [19]. We included pa-
tients with progressive muscular atrophy (PMA) because
of similarities between PMA and ALS regarding clinical
course, genetic background and pathology in the spinal
cord [20]. For PMA patients, we used criteria that have
been described before: progressive lower motor neuron
signs and symptoms in 2 or more of the 4 regions (bul-
bar, cervical, thoracic and lumbar) with careful exclusion
of mimics such as multifocal motor neuropathy, and no
clinical upper motor neuron signs and symptoms [21].
In addition, two or more respiratory functions tests
(FVC, PCF, MIP, MEP or SNIP) had to be assessed at
least at the Radboudumc or HVS and at least one day-
time capillary blood gas sample had to be taken at the
HVS. We excluded patients with a diagnosis of primary
lateral sclerosis (PLS), and ALS and PMA patients with
severe bulbar impairment or other, physical or cognitive
impairments which made the application of NIV impos-
sible, as judged by the referring or HVS physician.
Study design, data collection and processing
This is a retrospective cohort study. Case records from
2008 up to 2015 were selected. Retrospectively designed
studies do not need approval by the local ethics commit-
tee. As all tests had been performed for clinical use, there
was no need to obtain informed consent. The following
data (anonymized by the main researcher) were retrieved:
1. Respiratory function tests during consecutive
outpatients visits: FVC (%predicted), PCF (L/min),
MIP (cm H2O), MEP (cm H2O) and SNIP (cm H2O).
2. Data of the first assessment and follow-up visits at
the HVS: Daytime capillary PCO2 and bicarbonate
levels, complaints of respiratory impairment (presence
of dyspnoea, orthopnoea, morning headache, fatigue
and excessive saliva; yes/no) and indication for NIV ini-
tiation (yes/no, as judged by the physician of the HVS)
Respiratory function tests
All tests were performed in the upright position, using
a spirometer (Spirostik; Geratherm Bad Kissingen,
Germany), a peak flow meter (MicroPeak™; CareFu-
sion, San Diego, USA) or a respiratory pressure meter
(Micro RPM™-120; Micro Medical Limited, Rochester,
England). All devices are standardized according to the
ATS/ERS Statement [22].
Forced vital capacity
FVC is the maximal volume of air exhaled with max-
imally forced effort from a maximal inspiration. The
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value is expressed as a percentage of the predicted value,
based on patient’s age and height [14].
Peak cough flow
PCF is measured by performing a maximal inspiration,
followed by a cough as forcefully as possible, while the
lips are sealed tightly around the tube [23].
Maximum inspiratory and expiratory pressure
MIP and MEP are measured by a non compressible face
mask. The MIP is retrieved by exhaling to residual volume
and then inhaling with as much effort as possible for at
least 3 s. The MEP is retrieved similarly but the opposite
way, by inhaling followed by a forced expiration. The max-
imum value of three manoeuvres is used for MIP and MEP,
expressed as cm H2O or % predicted value (calculated
according to reference values of Wilson et al.) [22, 24, 25].
Sniff nasal inspiratory pressure
SNIP is measured by inserting a nose piece or cone into
the nostril. The SNIP is retrieved by a maximal sniff
starting from relaxed end expiration, performed while
the contralateral nostril is closed by an occluding plug.
The maximum pressure value of five attempts is used,
expressed as cm H2O or % predicted value [22, 26].
Referral process of patients with ALS to home ventilation
services
Before referral to an HVS, patients are, on average, tri-
monthly monitored by one of the multidisciplinary ALS
care teams. A referral to an HVS is indicated when one
or more of the following occurs: FVC <70%, symptoms
of nocturnal hypoventilation, signs of increased breath-
ing activity or daytime hypercapnia (PCO2 > 45 mmHg)
[27]. Other respiratory parameters, such as PCF or SNIP,
are used infrequently in ALS clinics in Netherlands [4].
At the first HVS assessment, capillary blood gas analysis
is performed and an extensive medical history is taken, in-
cluding signs of nocturnal and daytime hypoventilation.
Also, patients are informed about the treatment options:
non-invasive ventilation (NIV); invasive ventilation by
tracheostomy (TPPV) or palliative care. If a patient opts for
ventilatory support in the future, his or her respiratory
function will be measured trimonthly at the HVS using the
FVC, PCF, MIP, MEP and SNIP to monitor disease progres-
sion. Elective NIV indications are made by HVS physicians
only. The NIV indication is based on either proven noc-
turnal or daytime hypercapnia, orthopnoea and/or other
complaints of nocturnal or daytime hypoventilation [9, 10].
Data and statistical analysis
Patients’ characteristics are reported as proportions and
mean ± standard deviation (SD). A time-curve was used
to evaluate the decline of the respiratory function tests
of patients with two or more consecutive measurements
before receiving an NIV indication. Differences in re-
spiratory function tests between 6 months and 3 months
before NIV indication and in the latest 3 months were
assessed by paired t-tests. To explore the test results of
patients who received an NIV indication, the value of
the FVC, PCF, MIP, MEP and SNIP was plotted against
the cumulative percent of patients with an NIV indica-
tion within the following 3 months. Based on these data,
tentative cut-off values were determined at an arbitrary
value of 85%, with a 95% confidence interval (the value
of 15% is a reduction of more than half compared to the
proportion of 37% in our previous study and is thought
to reflect a clinical relevant difference) [4]. Sensitivity
and specificity of these cut-off values, and cut-off values
of international guidelines were determined by ROC-
curves with the values of t = −3 as positive outcome and
values of t = −6 and t = −9 as negative outcome.
Respiratory function test results at the last visit at the
ALS clinic of the Radboudumc were compared between
two groups, stratified by NIV indication at the first visit
at the HVS, using an independent samples t-test, not as-
suming equal variances (Satterthwaite method).
All statistical analysis were done using IBM SPSS sta-
tistics version 23. A two-tailed p-value of <0.05 was con-
sidered significant.
Results
Medical records of 131 patients were examined (Fig. 1).
21 patients did not visit an HVS and were excluded from
this study. Table 1 shows the characteristics of the 110
included patients. Fifty-seven patients (52%) were re-
ferred to an HVS by the multidisciplinary ALS care team
at the Radboudumc. From 53 other patients, referred by
other ALS care teams, data were retrieved at the HVS in
Utrecht; no data concerning measurements at their ALS
care team were available.
Out of the 110 patients, 87 patients (79%) received an
NIV indication at the HVS; the remaining 23 patients
did not receive an NIV indication yet or died before re-
ceiving one. 12%, 21%, 28% and 40% of the patients had
1, 2, 3 or 4 or more assessments of respiratory function
tests before the NIV indication, respectively. All patients
had had at least one blood gas analysis at the HVS. After
receiving an NIV indication, 77 patients (89%) success-
fully accepted NIV more than 48 h. Out of the 77 pa-
tients, 4 patients chose to be ventilated by tracheostomy
when NIV was insufficient.
Decline in respiratory function
All five respiratory function tests showed a descending
trend between the trimonthly assessments. Average time
curves are displayed in Fig. 2a-e. The mean declines
within the last 3 months before the NIV indication were
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16% ±21(FVC, n = 67), 16% ±19 (PCF, n = 17), 18% ±30
(MIP, n = 64), 13% ±34(MEP, n = 64) and 22% ±28
(SNIP, n = 31), respectively; the difference between
t = −3 months and t = NIV indication was significant for
all tests (p < 0.001). The difference between t = −6 months
and t = −3 months was 16% (FVC; p < 0.001, n = 44),
2% (PCF; p = 0.219, n = 13), 18% (MIP; p < 0.001,
n = 43), 17% (MEP; p < 0.001, n = 42) and 15% (SNIP;
p < 0.007, n = 15), respectively.
Cut off values
Figure 3a-e shows values of respiratory function tests
against the cumulative percentage of patients with an
NIV indication within the following 3 months. Cut off
values were determined at a value where 85% of the pa-
tients received an NIV indication within 3 months,
shown in Table 2. Sensitivity and specificity were calcu-
lated for these cut-off values (Table 2). In addition, sen-
sitivity and specificity of previously published cut-off
values were determined. The ROC curves are shown in
Fig. 4a-e.
Respiratory function tests at the first HVS assessment
Out of the 57 patients of the Radboudumc (52% of the
110 included patients), 22 patients received an NIV indi-
cation at their first assessment at the HVS and were
classified as ‘NIV indication’; 35 other patients were
classified as ‘no NIV indication yet’. Table 3 shows the
characteristics of these groups. The mean age of the
‘NIV indication’ group was higher (69.8 ± 10.3 years),
Table 1 Characteristics of the included patients
All patients
(n = 110)
Demographic and disease variables
Male (%) 60.3
Diagnosis ALS/PMA (% ALS) 84.0
Onset spinal/bulbar/both (%) 60.3 / 23.7 / 16.0
Age at referral (years) 61.5 ± 12.0
Disease duration (years)° 2.0 ± 1.7
Mortality (n)° 67
Variables at first evaluation at the HVS
Interval referral and first HVS assessment (weeks) 5.6 ± 5.1
PCO2 (mmHg) 39.4 ± 5.6
Bicarbonate (mmol/L) 26.40 ± 3.69
Follow up until NIV (months)* 9 ± 8
Values are mean (SD) unless stated otherwise. Time of death was checked in
the Municipal Personal Database at January 1th, 2016 [38]. °Missing data of 20
patients, n = 90. *Only patients who received an NIV indication, n = 87. ALS
Amyotrophic lateral sclerosis, PMA Progressive Muscular Atrophy, HVS Home
ventilation services, NIV Non-invasive ventilation
Fig. 1 Flowchart of the patients. The dotted box indicates the patients included for analyses. *21 patients who did not yet receive a referral to an
Home Ventilation Services (HVS) or died before. NIV: Non-invasive ventilation (successfully accepted (n = 77) use >48 h), ALS: Amyotrophic Lateral
Sclerosis, PMA: Progressive Muscular Atrophy
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than the ‘no NIV indication yet’ group (61.4 ± 13.1 years),
p = 0.014. In Table 4, the respiratory function tests and
complaints (at time of referral) are displayed for groups
stratified by NIV indication at the first HVS visit. The
time between the last assessment at the ALS clinic and
the first visit at the HVS was 6 ± 5 weeks and showed a
trend towards a shorter interval in the patients who
received an NIV indication compared to the ‘no NIV in-
dication yet’ group (4 ± 3) vs. 7 ± 6; p = 0.056). The
mean (SD) PCF was lower in the ‘NIV indication’ group
compared to the ‘no NIV indication yet’ group
(259 ± 92 L/min vs. 348 ± 135 L/min, p = 0.019). Com-
plaints of nocturnal hypoventilation (assessed at the ALS
care team at the Radboudumc) tended to be more fre-
quent in patients with an NIV indication (17 out of 22),
compared to the group with no NIV indication yet (18
out of 35), p = 0.051.
Discussion
The present study examined serial data (trimonthly) of
five respiratory function tests (FVC, PCF, MIP, MEP and
Fig. 2 Time-curves of patients with 2 or more consecutive measurements. a FVC: Forced Vital Capacity (% predicted value), n = 2, 3, 9, 17, 28, 43,
67, 67; respectively. b PCF: Peak Cough Flow (L/min), n = 2, 4, 8, 10, 12, 21, 24, 24; respectively. c MIP: Maximum Inspiratory Pressure (cm H2O),
n = 2, 3, 9, 15, 24, 38, 64, 64; respectively. e MEP: Maximum Expiratory Pressure (cm H2O), n = 2, 3, 8, 15, 24, 38, 64, 64; respectively. e SNIP: Sniff
Nasal Inspiratory Pressure (cm H2O), n = 1, 1, 3, 3, 7, 12, 31, 31; respectively. Data are presented as mean (SD) and time intervals are presented in
months before the indication of non-invasive ventilation (NIV)
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SNIP) in patients with ALS in order to determine their
predictive value for NIV indication. The main findings
of this study are: (1) PCF has the largest predictive value
for NIV indication, with a significant discrimination be-
tween ‘NIV indication’ patients and ‘no NIV indication
yet’ patients at their first HVS visit; (2) all of the tests
showed a descending trend with a significant difference in
the last months before the NIV indication (p < 0.001), and
SNIP showed the greatest decline. Below we discuss our
findings according to three tests: FVC; PCF and SNIP.
Forced vital capacity
Supine FVC has shown the ability to detect diaphrag-
matic weakness [28] and guidelines suggest that referral
to an HVS is indicated when FVC is <70% of the
predicted value [27]. Previous cross-sectional studies
however, have demonstrated the limitations of the FVC
in terms of detection of early respiratory dysfunction
(and as such as a criterion for timely referral to an HVS)
[4, 11, 12]. One could assume that by using longitudinal
data, the FVC may have a better predictive value,
Fig. 3 Respiratory function tests plotted against the proportion of patients with an NIV indication within the following 3 months. a FVC: Forced
Vital Capacity (% predicted value), n = 72; b PCF: Peak Cough Flow (L/min), n = 24; c MIP: Maximum Inspiratory Pressure (cm H2O), n = 70; d MEP:
Maximum Expiratory Pressure (cm H2O), n = 70; e SNIP: Sniff Nasal Inspiratory Pressure (cm H2O), n = 38. NIV: Non-invasive ventilation. For example,
15% of the patients had a PCF of 386 L/min or more in the 3 months before their NIV indication
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however the present retrospective study corroborates
the restricted value of FVC to detect imminent respira-
tory insufficiency, even if serial data are used. Data of
the current study show that when using an FVC <70%
of the predicted value, 35% of the patients are inadvert-
ently not referred to an HVS within the following 3
months, while they could have benefitted from such a
referral [4]. This proportion is comparable to our previ-
ous study [4] and are in line with a recent study of
Polkey et al., who investigated the predictive value of in-
vasive and non-invasive respiratory muscle strength as-
sessments for survival or ventilator-free survival. The
latter study showed a good predictive power of FVC for
ventilation-free survival, but the cut off value indicating
a poor prognosis, lies within the normal or near normal
range (>80% predicted) [29].
Peak cough flow
As respiratory muscle weakness leads to impaired cough
with a lower PCF, we hypothesized that a decline of the
PCF may predict the need for NIV in the following
months [14]. Indeed, time curves of serial PCF measure-
ments showed a decline of 16% before receiving an NIV
indication in the last 3 months. A similar percentage has
been found by others who used peak expiratory flow
time (PEFT). PEFT increased significantly (indicating
more impairment) and linearly with time, 4.7% per
month (p < 0.001), which is comparable to our findings
(PCF −16% in 3 months = −5.3% per month) [30, 31].
Polkey et al. also showed a descending trend of the peak
cough pressure in the months previous to NIV or death
[29]. Our data further showed that the PCF, as measured
5.6 weeks before the first HVS assessment, was the only
test that discriminated ‘NIV indication’ from ‘no NIV in-
dication yet’ patients. A predictive value of PCF for the
need for NIV has been found previously in patients with
ALS who had an acute lower respiratory tract infection
[16]. Together, our findings and previous findings by
others suggest the value of PCF, which should lead to
more frequent use of this measure during the respiratory
care of patients with ALS [29–31]. A national survey
among referring physicians in the Netherlands suggests
room for improvement: PCF was routinely used by half
of Dutch ALS physicians (paper in preparation). In a
comparable national survey in the UK, the PCF was not
included [5].
Patients with an NIV indication were older at the time
of referral than the ‘no NIV indication yet’ group. In nor-
mal subjects, PCF is generally >500 L/min for all ages
[32]. Previous studies showed an (inverse) age effect of
the Maximum Expiratory Flow (MEF) and Peak Expira-
tory Flow (PEF), which was, however, limited when dis-
ease effects were excluded [33, 34]. The effect of age on
the PCF has been shown in three age groups: 8–15 years,
16–35 years and >36 years; however, we are not aware of
an important age effect at ≥60 years [34]. Although we
cannot exclude a small effect, it is unlikely that the PCF
difference of 89 L/min is due to an age difference.
Sniff nasal inspiratory pressure
The difference of the SNIP value between ‘NIV indication’
and ‘no NIV indication yet’ patients was considerable: 28
vs. 40% of the predicted value, although not statistically
significant. The latter is probably related to the relatively
low number of patients with (serial) SNIP measurements
(n = 20 in our study), in particular when we consider
previous findings of the SNIP being able to detect hy-
percapnia, nocturnal hypoventilation or survival in ALS
[11, 29, 35, 36]. The significant descent of SNIP values in
the months before receiving NIV in our study and (prior
to NIV or death) in another study (n = 78) corroborates
the importance of SNIP measurements in the clinical as-
sessment of patients with ALS and possible deterioration
of respiratory muscle strength [29].
Similarly to the PCF, the SNIP is performed routinely by
only a limited number of physicians in the Netherlands
(13%; paper in preparation). In the UK 4% of the physi-
cians used the SNIP routinely and 13% of the physicians
used SNIP only if patients were symptomatic [5].
Table 2 Cut-off values for referral to the home ventilation services
Suggested values Guideline values [9, 15, 27]
Cut-off value Sensitivity Specificity Cut-off value Sensitivity Specificity
FVC 95 (77–104) 85 22 70 65 50
PCF 386 (356–472) 88 36 300 33 67
MIP 67 (52–74) 85 27 60 82 35
MEP 74 (66–90) 85 38 60 68 56
SNIP 45 (41–59) 87 40 40 71 50
Cut-off values are presented as value (95% CI). The sensitivity and specificity are calculated with an ROC curve analysis. ALS Amyotrophic Lateral Sclerosis, HVS Home
Ventilation Services, NIV Non-invasive ventilation, FVC Forced Vital Capacity (% predicted value), PCF Peak Cough Flow (L/min.), MIP and MEP Maximum Inspiratory and
Expiratory Pressure (cm H2O), SNIP Sniff Nasal Inspiratory Pressure (cm H2O)
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Timing and site of onset
The cut-off values that were determined resulted in a high
sensitivity to predict an NIV indication within the follow-
ing 3 months, however specificity was low. This implies
that the number of false positive referrals to an HVS is
relatively high. However, in our opinion, an early referral
is preferable compared to a late referral considering the
importance for patients with ALS to make a decision
about the possible treatment options. Costs and burden of
non invasive respiratory function tests are minimal and
Fig. 4 ROC curves. a FVC: Forced Vital Capacity (% predicted value); b PCF: Peak Cough Flow (L/min); c MIP: Maximum Inspiratory Pressure (cm
H2O); d MEP: Maximum Expiratory Pressure (cm H2O); e SNIP: Sniff Nasal Inspiratory Pressure (cm H2O). The graphs are calculated with the values
of the measurements of t = −3 as positive outcome and of t = −6 and t = −9 as negative outcome
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compensates the benefit of a timely or even early start of
NIV: it has proven to postpone the decrease of respiratory
muscle strength and thereby prolong survival [37].
Although bulbar onset can be challenging for NIV to be
effective, a recent survey among Dutch referring physi-
cians showed that only 16% stated bulbar impairment as a
reason to refrain from referral (paper in preparation).
Current practice, at least in the Netherlands, does not ex-
clude these patients form referral to an HVS.
In addition to the strengths of this study (analysis of
serial measurements and combining data of an ALS care
team and an HVS), one of the limitations is the retro-
spective design, which is the main reason for the missing
values of respiratory function measurements.
Conclusion
Out of five respiratory function tests, PCF and SNIP
have the best predictive value for an NIV indication in
patients with ALS. We therefore recommend to use PCF
and SNIP more often during the follow-up of patients
with ALS. Our findings and proposed cut offs, may serve
as a starting point for future research, aimed at optimal re-
ferral of patients with ALS to an HVS, in order to avoid
emergency initiation of NIV as much as possible [6].
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Table 3 Characteristics of the patients of the Radboudumc
All patients
(n = 57)
No NIV indication
(n = 35, 61.4%)
NIV indication
(n = 22, 38.6%)
P-value
Demographic and disease variables
Male (%) 50.9 54.3 45.5 0.516
Diagnosis ALS/PMA (% ALS) 87.7 88.6 86.4 0.805
Onset Spinal/Bulbar/Both (%) 45.6 / 36.8 / 17.5 40.0 / 37.1 / 22.9 54.5 / 36.4 / 9.1 0.352
Age at referral (years) 64.6 ± 12.7 61.4 ± 13.1 69.8 ± 10.3 0.014
Disease duration (years) 1.9 ± 1.6 2.0 ± 1.6 1.8 ± 1.8 0.572
Deceased (n) 34 19 15 0.298
Variables at HVS
Interval referral and first assessment (weeks) 5.6 ± 5.1 6.6 ± 5.9 4.1 ± 2.9 0.056
pCO2 at first evaluation (mmHg) 40.6 ± 6.3 37.92 ± 3.19 44.95 ± 7.70 <0.0001
Bicarbonate at first evaluation (mmol/L) 26.7 ± 3.7 25.08 ± 2.51 29.23 ± 3.88 <0.0001
Follow up until NIV (months)* 12 ± 6 12 ± 6 0 ± 0 -
The groups are based on the presence of an NIV indication during the first assessment at the HVS. Values are mean ± SD unless stated otherwise. P-values:
comparison between patients with and without an NIV indication at the first visit at the HVS, using t-tests and Pearson Chi-square. ALS Amyotrophic Lateral Sclerosis,
PMA Progressive Muscular Atrophy, HVS Home Ventilation Services, NIV Non-invasive ventilation. *Only patients who received an NIV indication
Table 4 Comparison of respiratory function tests and complaints
at referral, between patients with and without an NIV indication at
the first home ventilation service visit
No NIV indication
yet (n = 35)
NIV indication
(n = 22)
N N Difference (SE) P-value
FVC 32 79 ± 21 20 70 ± 20 −9.9 ± 6 0.101
PCF 24 348 ± 137 16 259 ± 92 −88.4 ± 39 0.019
MIP 28 59 ± 36 19 50 ± 26 −8.9 ± 9 0.338
MEP 29 46 ± 23 18 44 ± 21 −1.9 ± 7 0.774
SNIP 15 40 ± 18 5 28 ± 9 −12 ± 12 0.089
Complaints 35 51% 22 77% 0.051
Data are presented as mean ± SD or proportion. These data are collected
at the Radboudumc at the time of referral to the HVS. The NIV indication
was made at the first visit at the HVS. Median time between referral and
the first visit at the HVS was 5.6 weeks (range 4.4–7.0). HVS Home Ventilation
Services, NIV Non-invasive ventilation, FVC Forced Vital Capacity (% predicted
value), PCF Peak Cough Flow (L/min.), MIP and MEP Maximum Inspiratory
and Expiratory Pressure (% predicted value), SNIP Sniff Nasal Inspiratory
Pressure (% predicted value)
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